# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Purpose</td>
<td>2</td>
</tr>
<tr>
<td>2. Scope</td>
<td>2</td>
</tr>
<tr>
<td>3. Definitions</td>
<td>2</td>
</tr>
<tr>
<td>4. Policy Statements</td>
<td>2-3</td>
</tr>
<tr>
<td>5. Procedures</td>
<td>3</td>
</tr>
</tbody>
</table>

**Cross References; References; Prior Version Dates**

**Appendices**

- **CRITERIA FOR DETERMINING MDRO STATUS**: APPENDIX A
- **TRANSMISSION BASED PRECAUTIONS BY PATIENT AND LOCATION**: APPENDIX B
- **ALGORITHM FOR CLINICAL MANAGEMENT OF PATIENTS IN HOSPITAL SETTINGS AT AURORA HEALTH CARE**: APPENDIX C
1. **PURPOSE**

The purpose of this policy is to prevent transmission, acquisition, or emergence of multidrug resistant organisms to patients, caregivers, and visitors.

2. **SCOPE**

This policy applies to Aurora Health Care, Inc. and any entity or facility owned or controlled by Aurora Health Care.

3. **DEFINITIONS**

**Multidrug-resistant organisms (MDROs):** organisms that have resistance to one or more classes of antibiotics (See Appendix A).

**Colonization:** the presence of a microorganism on or within a body site, without the body showing symptoms or clinical manifestations of illness or infection.

**Infection:** presence of a microorganism evading or overcoming the defense mechanisms on or within a body site, resulting in the manifestations of disease. Body responses may include clinical symptoms and/or subclinical symptoms of illness or infection.

**Susceptible:** an organism is called "susceptible" to a drug when the infection caused by it is likely to respond to treatment with this drug, at the recommended dosage.

**Resistance:** organism is expected not to respond to a given drug, irrespective of the dosage and of the location of the infection.

**Intermediate:** isolates with antimicrobial minimum inhibitory concentrations that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. The intermediate category implies clinical efficacy in body sites where the drugs are physiologically or when a higher than normal dosage of a drug can be used.

4. **POLICY**

4.1 Organisms identified as MDROs (See Appendix A) will be decided upon by Aurora Health Care Infection Prevention, Antimicrobial Stewardship, and Infection Prevention Leadership, in consultation with ACL Microbiology personnel.

4.2 An annual Risk Assessment will be completed to review current risk and trends of MDROs for each hospital, non-hospital ambulatory clinic, and Aurora at Home. The Risk Assessment will be reviewed and approved annually by the site Infection Control Committee or other appropriate committee as designated by area leadership.

4.3 Transmission-Based Precautions will be followed according to **STANDARD AND TRANSMISSION-BASED PRECAUTIONS ISOLATION**

Education related to the type of precaution and the procedures to be adhered to, the importance of Hand Hygiene and their responsibility in reducing the transmission of pathogens must be provided to patients/families/visitors. The education delivered and patient/visitor/family understanding and response to the education must be documented in the inpatient medical record according to **STANDARD AND TRANSMISSION-BASED DETECTION AND INFECTION CONTROL INSTRUCTIONS**.
PRECAUTIONS ISOLATION. Nursing staff provide oversight of patient/visitor/family member education and compliance with the posted transmission based precautions and the use of PPE.

4.4 Patient’s MDRO status will be shared with other facilities if the patient is transferred.

5 PROCEDURE

5.4 Refer to Appendix B, to identify the type of transmission-based precaution, when to initiate the appropriate precaution, and when to remove from isolation. Nursing may initiate isolation precautions and place the order in Epic using the order mode “No Co-Sign Required” with the Ordering and Authorizing physician’s name. A physician order is needed to discontinue an isolation order.

5.5 Infection Prevention will refer to Appendix B for the removal of the MDRO flag in a patient’s electronic medical record.

5.6 Infection Prevention will refer to Appendix C for MDRO vs CRE management of patients in hospital settings (CRE Algorithm). Algorithm 1 defines CRE per Aurora Health.

CROSS REFERENCES:
- ACL Reference 4710 "Usual Antimicrobial Resistance"
- PREVENTION AND CONTROL OF MRSA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
- STANDARD AND TRANSMISSION-BASED PRECAUTIONS ISOLATION

REFERENCES:
  www.cdc.gov/hai/organisms/cre/

PRIOR REVIEW / REVISION DATES: